Showing results (1-10 of 549) with videos related to

Sort By:
Pageof 55
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|August 10, 2000
Laboratory tests for neuroendocrine tumoursE Seregni, L Ferrari, M Stivanello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapyL Dogliotti, M Tampellini, M Stivanello, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|July 18, 2001
Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumorsE Seregni, A Martinetti, L Ferrari, et al.
Seminars in Surgical Oncology|June 9, 2001
Diagnostic and prognostic tumor markers in the gastrointestinal tractE Seregni, L Ferrari, A Martinetti, et al.
The International Journal of Biological Markers|November 6, 1998
Immunosuppressive factors: role in cancer development and progressionC Botti, E Seregni, L Ferrari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Clinical significance of blood chromogranin A measurement in neuroendocrine tumoursE Seregni, L Ferrari, E Bajetta, et al.
Anticancer Research|January 12, 2000
The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumoursL Ferrari, E Seregni, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experienceM Stivanello, A Berruti, M Torta, et al.
The International Journal of Biological Markers|May 16, 1998
Bladder cancer monitoring using two novel urinary markersC Botti, E Seregni, S Mattioli, et al.
Anticancer Research|May 5, 1999
The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-Medronate incorporationS N Molteni, E Seregni, C Botti, et al.
Pageof 55